

# Giancarlo Logroscino

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7383345/publications.pdf>

Version: 2024-02-01

343  
papers

44,362  
citations

4942

84  
h-index

2375

198  
g-index

348  
all docs

348  
docs citations

348  
times ranked

59045  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phosphorylated TDP-43 aggregates in peripheral motor nerves of patients with amyotrophic lateral sclerosis. <i>Brain</i> , 2022, 145, 276-284.	3.7	22
2	FRONTotemporal dementia Incidence European Research Studyâ€”FRONTIERS: Rationale and design. <i>Alzheimer's and Dementia</i> , 2022, 18, 498-506.	0.4	12
3	Incidence, prevalence and disability associated with neurological disorders in Italy between 1990 and 2019: an analysis based on the Global Burden of Disease Study 2019. <i>Journal of Neurology</i> , 2022, 269, 2080-2098.	1.8	21
4	<i>Neuroepidemiology</i> , 2022, , 215-225.		0
5	Altered structural brain networks in linguistic variants of frontotemporal dementia. <i>Brain Imaging and Behavior</i> , 2022, 16, 1113-1122.	1.1	9
6	The diagnostic accuracy of late-life depression is influenced by subjective memory complaints and educational level in an older population in Southern Italy. <i>Psychiatry Research</i> , 2022, 308, 114346.	1.7	3
7	Imaging correlates of depression in progressive supranuclear palsy. <i>Journal of Neurology</i> , 2022, 269, 3522-3528.	1.8	6
8	Magnetic Resonance Parkinsonism Index Is Associated with REM Sleep Behavior Disorder in Parkinsonâ€™s Disease. <i>Brain Sciences</i> , 2022, 12, 202.	1.1	3
9	The Latin American Epidemiology Network for ALS (Laenals). <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 372-377.	1.1	5
10	Glycomic and Glycoproteomic Techniques in Neurodegenerative Disorders and Neurotrauma: Towards Personalized Markers. <i>Cells</i> , 2022, 11, 581.	1.8	13
11	Alzheimer's disease research progress in the Mediterranean region: The Alzheimer's Association International Conference Satellite Symposium. <i>Alzheimer's and Dementia</i> , 2022, 18, 1957-1968.	0.4	2
12	Neuroimaging Findings in a Patient with Anti-IgLON5 Disease: Cerebrospinal Fluid Dynamics Abnormalities. <i>Diagnostics</i> , 2022, 12, 849.	1.3	4
13	Answer to â€œSocial cognition assessment for mild neurocognitive disordersâ€. <i>Alzheimer's and Dementia</i> , 2022, 18, 1441-1442.	0.4	3
14	The burden of mental disorders, substance use disorders and self-harm among young people in Europe, 1990â€”2019: Findings from the Global Burden of Disease Study 2019. <i>Lancet Regional Health - Europe</i> , 2022, 16, 100341.	3.0	70
15	Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. <i>JAMA Network Open</i> , 2022, 5, e229588.	2.8	18
16	Decipher nonâ€œcanonical <i>SPAST</i> splicing mutations with the help of functional assays in patients affected by spastic paraplegia 4 ( <i>SPG4</i> ). <i>Clinical Genetics</i> , 2022, 102, 155-156.	1.0	2
17	Cerebral Venous Thrombosis after SARS-CoV-2 Infection and Pfizer-BioNTech Vaccination against COVID-19. <i>Diagnostics</i> , 2022, 12, 1253.	1.3	2
18	Role of plasma phosphorylated neurofilament heavy chain (pNfH) in amyotrophic lateral sclerosis. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 3608-3615.	1.6	5

#	ARTICLE	IF	CITATIONS
19	Retinal Vascular Density on Optical Coherence Tomography Angiography and Age-Related Central and Peripheral Hearing Loss in a Southern Italian Older Population. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 2169-2177.	1.7	6
20	Burden of Neurological Disorders Across the US From 1990-2017. <i>JAMA Neurology</i> , 2021, 78, 165.	4.5	262
21	The Modified Five-Point Test (MFPT): normative data for a sample of Italian elderly. <i>Neurological Sciences</i> , 2021, 42, 2431-2440.	0.9	2
22	Late-onset depression is associated to age-related central auditory processing disorder in an older population in Southern Italy. <i>GeroScience</i> , 2021, 43, 1003-1014.	2.1	6
23	FNDC5/Irisin System in Neuroinflammation and Neurodegenerative Diseases: Update and Novel Perspective. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1605.	1.8	61
24	The links between diabetes mellitus and amyotrophic lateral sclerosis. <i>Neurological Sciences</i> , 2021, 42, 1377-1387.	0.9	18
25	Brain Structural Covariance Networks in Behavioral Variant of Frontotemporal Dementia. <i>Brain Sciences</i> , 2021, 11, 192.	1.1	10
26	Time-trend evolution and determinants of sex ratio in Amyotrophic Lateral Sclerosis: a doseâ€“response meta-analysis. <i>Journal of Neurology</i> , 2021, 268, 2973-2984.	1.8	13
27	Being the Family Caregiver of a Patient With Dementia During the Coronavirus Disease 2019 Lockdown. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 653533.	1.7	39
28	Comparison of the ability of the Kingâ€™s and MiToS staging systems to predict disease progression and survival in amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 1-9.	1.1	6
29	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. <i>Biological Psychiatry</i> , 2021, 89, 825-835.	0.7	10
30	Dietary Habits and Nutrient Intakes Are Associated to Age-Related Central Auditory Processing Disorder in a Cohort From Southern Italy. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 629017.	1.7	4
31	Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis. <i>Nature Medicine</i> , 2021, 27, 1197-1204.	15.2	96
32	Association Between Central and Peripheral Age-Related Hearing Loss and Different Frailty Phenotypes in an Older Population in Southern Italy. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2021, 147, 561.	1.2	31
33	Cohort Analysis of 67 Charcot-Marie-Tooth Italian Patients: Identification of New Mutations and Broadening of Phenotype Expression Produced by Rare Variants. <i>Frontiers in Genetics</i> , 2021, 12, 682050.	1.1	4
34	Hearing Function: Identification of New Candidate Genes Further Explaining the Complexity of This Sensory Ability. <i>Genes</i> , 2021, 12, 1228.	1.0	1
35	Reduction of Sniff Nasal Inspiratory Pressure (SNIP) as an Early Indicator of the Need of Enteral Nutrition in Patients with Amyotrophic Lateral Sclerosis. <i>Brain Sciences</i> , 2021, 11, 1091.	1.1	1
36	Association of Variants in the <i>SPTLC1</i> Gene With Juvenile Amyotrophic Lateral Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 1236.	4.5	46

#	ARTICLE	IF	CITATIONS
37	The Role of Age on Beta-Amyloid <sup>1</sup> 42 Plasma Levels in Healthy Subjects. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 698571.	1.7	8
38	Suicidal behaviour in older age: A systematic review of risk factors associated to suicide attempts and completed suicides. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 127, 193-211.	2.9	54
39	Autism Spectrum Disorder and Prenatal or Early Life Exposure to Pesticides: A Short Review. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 10991.	1.2	12
40	Delusion and Delirium in Neurodegenerative Disorders: An Overlooked Relationship?. <i>Frontiers in Psychiatry</i> , 2021, 12, 808724.	1.3	4
41	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. <i>Nature Genetics</i> , 2021, 53, 1636-1648.	9.4	223
42	Effect modification of the association between total cigarette smoking and ALS risk by intensity, duration and time-since-quitting: Euro-MOTOR. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 33-39.	0.9	20
43	The Reconstructed Cohort Design: A Method to Study Rare Neurodegenerative Diseases in Population-Based Settings. <i>Neuroepidemiology</i> , 2020, 54, 114-122.	1.1	13
44	Incidence of dementia in the oldest-old and its relationship with age: The Monzino 80+ population-based study. <i>Alzheimer's and Dementia</i> , 2020, 16, 472-481.	0.4	17
45	Clinical features and outcomes of the flail arm and flail leg and pure lower motor neuron MND variants: a multicentre Italian study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1001-1003.	0.9	14
46	Telemedicine for Delivery of Care in Frontotemporal Lobar Degeneration During COVID-19 Pandemic: Results from Southern Italy. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 481-489.	1.2	35
47	Behavioral and Psychological Effects of Coronavirus Disease-19 Quarantine in Patients With Dementia. <i>Frontiers in Psychiatry</i> , 2020, 11, 578015.	1.3	157
48	Frontal lobe syndrome and dementias. , 2020, , 617-632.		1
49	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. <i>Scientific Reports</i> , 2020, 10, 12184.	1.6	4
50	Traditional Old Dietary Pattern of Castellana Grotte (Apulia) Is Associated with Healthy Outcomes. <i>Nutrients</i> , 2020, 12, 3097.	1.7	11
51	Prevention of Alzheimer's disease and dementia: the evidence is out there, but new high-quality studies and implementation are needed. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1140-1141.	0.9	0
52	Plasma Inflammatory Cytokines Are Elevated in ALS. <i>Frontiers in Neurology</i> , 2020, 11, 552295.	1.1	48
53	Environmental Issues and Neurological Manifestations Associated with COVID-19 Pandemic: New Aspects of the Disease?. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8049.	1.2	35
54	Telemedicine is a useful tool to deliver care to patients with Amyotrophic Lateral Sclerosis during COVID-19 pandemic: results from Southern Italy. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 542-548.	1.1	36

#	ARTICLE	IF	CITATIONS
55	The importance of maintaining the same order of performance of lung function and SNIP tests in patients with amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 337-343.	1.1	3
56	COVID-19 Infection and Neurological Complications: Present Findings and Future Predictions. <i>Neuroepidemiology</i> , 2020, 54, 364-369.	1.1	49
57	Focus on the heterogeneity of amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 485-495.	1.1	32
58	Relationship between Inflammatory Food Consumption and Age-Related Hearing Loss in a Prospective Observational Cohort: Results from the Salus in Apulia Study. <i>Nutrients</i> , 2020, 12, 426.	1.7	40
59	Performance of risk prediction scores for cardiovascular mortality in older persons: External validation of the SCORE OP and appraisal. <i>PLoS ONE</i> , 2020, 15, e0231097.	1.1	4
60	Age-Related Central Auditory Processing Disorder, MCI, and Dementia in an Older Population of Southern Italy. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 163, 348-355.	1.1	39
61	The Italian Version of the Test Your Memory (TYM-I): A Tool to Detect Mild Cognitive Impairment in the Clinical Setting. <i>Frontiers in Psychology</i> , 2020, 11, 614920.	1.1	4
62	The Impact of COVID-19 Quarantine on Patients With Dementia and Family Caregivers: A Nation-Wide Survey. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 625781.	1.7	85
63	Association between alcohol exposure and the risk of amyotrophic lateral sclerosis in the Euro-MOTOR study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 11-19.	0.9	26
64	Biopsychosocial frailty and the risk of incident dementia: The Italian longitudinal study on aging. <i>Alzheimer's and Dementia</i> , 2019, 15, 1019-1028.	0.4	47
65	Predictors of diagnostic delay in amyotrophic lateral sclerosis: a cohort study based on administrative and electronic medical records data. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019, 20, 176-185.	1.1	34
66	<p>Early pathological gambling in co-occurrence with semantic variant primary progressive aphasia: a case report</p>. <i>Clinical Interventions in Aging</i> , 2019, Volume 14, 727-733.	1.3	3
67	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. <i>JAMA Neurology</i> , 2019, 76, 1035.	4.5	455
68	The Age-Related Central Auditory Processing Disorder: Silent Impairment of the Cognitive Ear. <i>Frontiers in Neuroscience</i> , 2019, 13, 619.	1.4	70
69	Associations of Cognitive Function and Education Level With All-Cause Mortality in Adults on Hemodialysis: Findings From the COGNITIVE-HD Study. <i>American Journal of Kidney Diseases</i> , 2019, 74, 452-462.	2.1	24
70	Comparative Analysis of C9orf72 and Sporadic Disease in a Large Multicenter ALS Population: The Effect of Male Sex on Survival of C9orf72 Positive Patients. <i>Frontiers in Neuroscience</i> , 2019, 13, 485.	1.4	35
71	Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1091-1107.	0.9	15
72	Incidence of frontotemporal lobar degeneration in Italy. <i>Neurology</i> , 2019, 92, e2355-e2363.	1.5	35

#	ARTICLE	IF	CITATIONS
73	Comparison of the clinical and genetic features of amyotrophic lateral sclerosis across Cuban, Uruguayan and Irish clinic-based populations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 659-665.	0.9	18
74	Episodic memory and learning rates in amyotrophic lateral sclerosis without dementia. <i>Cortex</i> , 2019, 117, 257-265.	1.1	9
75	Comparative evaluation of two immunoassays for cerebrospinal fluid $\beta$ -Amyloid $_{1-42}$ measurement. <i>Clinica Chimica Acta</i> , 2019, 493, 107-111.	0.5	9
76	Multicentre, population-based, case-control study of particulates, combustion products and amyotrophic lateral sclerosis risk. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 854-860.	0.9	17
77	Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , 2019, 18, 459-480.	4.9	2,625
78	Disease-modifying therapies for tauopathies: agents in the pipeline. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 397-408.	1.4	15
79	Amyotrophic lateral sclerosis mortality rates among ethnic groups in a predominant admixed population in Latin America: a population-based study in Ecuador. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019, 20, 404-412.	1.1	4
80	Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2019, 85, 470-481.	2.8	118
81	The Role of Biomarkers in Psychiatry. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1118, 135-162.	0.8	29
82	Anticholinergic burden before and after hospitalization in older adults with dementia: Increase due to antipsychotic medications. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 868-880.	1.3	13
83	A critical appraisal of amyloid- $\beta$ -targeting therapies for Alzheimer's disease. <i>Nature Reviews Neurology</i> , 2019, 15, 73-88.	4.9	666
84	Amyotrophic Lateral Sclerosis Descriptive Epidemiology: The Origin of Geographic Difference. <i>Neuroepidemiology</i> , 2019, 52, 93-103.	1.1	82
85	Are antibodies directed against amyloid- $\beta$ ( $A\beta$ ) oligomers the last call for the $A\beta$ hypothesis of Alzheimer's disease?. <i>Immunotherapy</i> , 2019, 11, 3-6.	1.0	50
86	Sensorial frailty: age-related hearing loss and the risk of cognitive impairment and dementia in later life. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231881100.	1.1	68
87	Loss of Swallow Tail Sign on Susceptibility-Weighted Imaging in Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 61-65.	1.2	15
88	Response to Letter to the Editor: "Plasma $\beta$ -amyloid $_{1-42}$ reference values". <i>Journal of the Neurological Sciences</i> , 2019, 396, 123-124.	0.3	0
89	Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , 2019, 18, 88-106.	4.9	1,512
90	Understanding frailty to predict and prevent dementia. <i>Lancet Neurology, The</i> , 2019, 18, 133-134.	4.9	19

#	ARTICLE	IF	CITATIONS
91	Multicentre, cross-cultural, population-based, case-control study of physical activity as risk factor for amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 797-803.	0.9	45
92	Different Cognitive Frailty Models and Health- and Cognitive-related Outcomes in Older Age: From Epidemiology to Prevention. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 993-1012.	1.2	214
93	Age-specific ALS incidence: a dose-response meta-analysis. <i>European Journal of Epidemiology</i> , 2018, 33, 621-634.	2.5	46
94	Prevalence and patterns of cognitive impairment in adult hemodialysis patients: the COGNITIVE-HD study. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1197-1206.	0.4	52
95	Pharmacotherapy for the treatment of depression in patients with Alzheimer's disease: a treatment-resistant depressive disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 823-842.	0.9	43
96	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. <i>Neuron</i> , 2018, 97, 1268-1283.e6.	3.8	517
97	An Old Challenge with New Promises: A Systematic Review on Comprehensive Geriatric Assessment in Long-Term Care Facilities. <i>Rejuvenation Research</i> , 2018, 21, 3-14.	0.9	25
98	Trauma and amyotrophic lateral sclerosis: a European population-based case-control study from the EURALS consortium. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2018, 19, 118-125.	1.1	26
99	Accuracy of clinical diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 358-366.	0.9	106
100	The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 25-35.	1.4	34
101	Qualitative analysis of the capacity to consent to treatment in patients with a chronic neurodegenerative disease: Alzheimer's disease / Analisi qualitativa sulla capacit� a prestare consenso al trattamento in pazienti con malattie cronico degenerative neuropsicoorganiche: Demenza di Alzheimer. <i>International Journal of Social Psychiatry</i> , 2018, 64, 26-36.	1.6	6
102	Sensory Changes and the Hearing Loss-Cognition Link. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2018, 144, 127.	1.2	16
103	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. <i>Brain</i> , 2018, 141, 2895-2907.	3.7	39
104	Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology</i> , The, 2018, 17, 939-953.	4.9	1,573
105	BACE inhibitors in clinical development for the treatment of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 847-857.	1.4	66
106	Other Neurocognitive Disorders in Tropical Health (Amyotrophic Lateral Sclerosis and Parkinson's) Tj ETQq0 0 0 rgBT /Ovgrlock 10 T		
107	Nutritional interventions and cognitive-related outcomes in patients with late-life cognitive disorders: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 95, 480-498.	2.9	27
108	Global, regional, and national burden of motor neuron diseases 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology</i> , The, 2018, 17, 1083-1097.	4.9	163

#	ARTICLE	IF	CITATIONS
109	Screening for Aphasia in NeuroDegeneration for the Diagnosis of Patients with Primary Progressive Aphasia: Clinical Validity and Psychometric Properties. <i>Dementia and Geriatric Cognitive Disorders</i> , 2018, 46, 243-252.	0.7	19
110	Referral bias in ALS epidemiological studies. <i>PLoS ONE</i> , 2018, 13, e0195821.	1.1	22
111	How complete is the information on preadmission psychotropic medications in inpatients with dementia? A comparison of hospital medical records with dispensing data. <i>International Journal of Methods in Psychiatric Research</i> , 2018, 27, e1724.	1.1	1
112	Social Dysfunction in Older Age and Relationships with Cognition, Depression, and Apathy: The GreatAGE Study. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 989-1000.	1.2	42
113	Plasma $\beta$ -amyloid $\beta$ 42 reference values in cognitively normal subjects. <i>Journal of the Neurological Sciences</i> , 2018, 391, 120-126.	0.3	19
114	Clinical features and genetic characterization of two dizygotic twins with C9orf72 expansion. <i>Neurobiology of Aging</i> , 2018, 69, 293.e1-293.e8.	1.5	1
115	Nutritional Intervention as a Preventive Approach for Cognitive-Related Outcomes in Cognitively Healthy Older Adults: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S229-S254.	1.2	38
116	Contribution of Mediterranean Diet in the Prevention of Alzheimer's Disease. , 2018, , 139-155.		3
117	Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. <i>International Journal of Epidemiology</i> , 2017, 46, dyw061.	0.9	202
118	The changing picture of amyotrophic lateral sclerosis: lessons from European registers. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 557-563.	0.9	89
119	Clinical and genetic analyses of familial and sporadic frontotemporal dementia patients in Southern Italy. <i>Alzheimer's and Dementia</i> , 2017, 13, 858-869.	0.4	24
120	Benefits, pitfalls, and future design of population-based registers in neurodegenerative disease. <i>Neurology</i> , 2017, 88, 2321-2329.	1.5	48
121	Midlife Metabolic Profile and the Risk of Late-Life Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 121-130.	1.2	41
122	Critical issues in ALS case-control studies: the case of the Euro-MOTOR study. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2017, 18, 411-418.	1.1	16
123	Premature mortality of epilepsy in low- and middle-income countries: A systematic review from the Mortality Task Force of the International League Against Epilepsy. <i>Epilepsia</i> , 2017, 58, 6-16.	2.6	120
124	Reversible Cognitive Frailty, Dementia, and All-Cause Mortality. The Italian Longitudinal Study on Aging. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 89.e1-89.e8.	1.2	126
125	Anti-tau vaccine in Alzheimer's disease: a tentative step. <i>Lancet Neurology</i> , The, 2017, 16, 99-100.	4.9	10
126	Three Decades of Comprehensive Geriatric Assessment: Evidence Coming From Different Healthcare Settings and Specific Clinical Conditions. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 192.e1-192.e11.	1.2	277



#	ARTICLE	IF	CITATIONS
127	Relationships of Dietary Patterns, Foods, and Micro- and Macronutrients with Alzheimer's Disease and Late-Life Cognitive Disorders: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 815-849.	1.2	249
128	Amyotrophic lateral sclerosis. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17071.	18.1	885
129	Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1373-1385.	1.0	8
130	A case-control study of hormonal exposures as etiologic factors for ALS in women. <i>Neurology</i> , 2017, 89, 1283-1290.	1.5	48
131	Cognitive frailty: a potential target for secondary prevention of dementia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 1023-1027.	1.5	40
132	Comorbidity of dementia with amyotrophic lateral sclerosis (ALS): insights from a large multicenter Italian cohort. <i>Journal of Neurology</i> , 2017, 264, 2224-2231.	1.8	19
133	Primary progressive aphasia: a review of neuropsychological tests for the assessment of speech and language disorders. <i>Aphasiology</i> , 2017, 31, 1359-1378.	1.4	16
134	Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet Neurology</i> , The, 2017, 16, 877-897.	4.9	1,521
135	Innovative biomarkers in psychiatric disorders: a major clinical challenge in psychiatry. <i>Expert Review of Proteomics</i> , 2017, 14, 809-824.	1.3	36
136	Characteristics and Prognosis of Oldest Old Subjects with Amyotrophic Lateral Sclerosis. <i>Neuroepidemiology</i> , 2017, 49, 64-73.	1.1	13
137	Additive Role of a Potentially Reversible Cognitive Frailty Model and Inflammatory State on the Risk of Disability: The Italian Longitudinal Study on Aging. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 1236-1248.	0.6	90
138	Factors predicting survival in ALS: a multicenter Italian study. <i>Journal of Neurology</i> , 2017, 264, 54-63.	1.8	96
139	Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 259-277.	1.5	13
140	The burden of premature mortality of epilepsy in high-income countries: A systematic review from the Mortality Task Force of the International League Against Epilepsy. <i>Epilepsia</i> , 2017, 58, 17-26.	2.6	228
141	Sensory impairments and cognitive disorders in older age. <i>Geriatric Care</i> , 2017, 3, .	0.2	0
142	Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease. <i>BioMed Research International</i> , 2016, 2016, 1-15.	0.9	138
143	Brain MR Contribution to the Differential Diagnosis of Parkinsonian Syndromes: An Update. <i>Parkinson's Disease</i> , 2016, 2016, 1-27.	0.6	16
144	Classification of Single Normal and Alzheimer's Disease Individuals from Cortical Sources of Resting State EEG Rhythms. <i>Frontiers in Neuroscience</i> , 2016, 10, 47.	1.4	73

#	ARTICLE	IF	CITATIONS
145	Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson's Disease? The Potential Role of Zolpidem in the Treatment of Parkinson's Disease. <i>Parkinson's Disease</i> , 2016, 2016, 1-14.	0.6	13
146	Warfarin Treatment and All-cause Mortality in Community-dwelling Older Adults with Atrial Fibrillation: A Retrospective Observational Study. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 1416-1424.	1.3	35
147	Psychiatry meets pharmacogenetics for the treatment of revolving door patients with psychiatric disorders. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 1357-1369.	1.4	10
148	Time to generalization and prediction of survival in patients with amyotrophic lateral sclerosis: a retrospective observational study. <i>European Journal of Neurology</i> , 2016, 23, 1117-1125.	1.7	19
149	A Novel Splice-Acceptor Site Mutation in GRN (c.709-2 A>T) Causes Frontotemporal Dementia Spectrum in a Large Family from Southern Italy. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 475-485.	1.2	12
150	Population-Based Evidence that Survival in Amyotrophic Lateral Sclerosis Is Related to Weight Loss at Diagnosis. <i>Neurodegenerative Diseases</i> , 2016, 16, 225-234.	0.8	39
151	Examination of level of knowledge in Italian general practitioners attending an education session on diagnosis and management of the early stage of Alzheimer's disease: pass or fail?. <i>International Psychogeriatrics</i> , 2016, 28, 1111-1124.	0.6	19
152	Bipolar Disorder and Frontotemporal Dementia: An Intriguing Association. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 973-979.	1.2	23
153	TBK1 is associated with ALS and ALS-FTD in Sardinian patients. <i>Neurobiology of Aging</i> , 2016, 43, 180.e1-180.e5.	1.5	40
154	Pseudobulbar affect (PBA) in an incident ALS cohort: results from the Apulia registry (SLAP). <i>Journal of Neurology</i> , 2016, 263, 316-321.	1.8	18
155	Emerging drugs to reduce abnormal $\beta$ -amyloid protein in Alzheimer's disease patients. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 377-391.	1.0	54
156	Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy. <i>Immunotherapy</i> , 2016, 8, 1119-1134.	1.0	61
157	Current Issues in Randomized Clinical Trials of Neurodegenerative Disorders at Enrolment and Reporting: Diagnosis, Recruitment, Representativeness of Patients, Ethnicity, and Quality of Reporting. <i>Frontiers of Neurology and Neuroscience</i> , 2016, 39, 24-36.	3.0	4
158	Hospitalizations due to respiratory failure in patients with Amyotrophic Lateral Sclerosis and their impact on survival: a population-based cohort study. <i>BMC Pulmonary Medicine</i> , 2016, 16, 136.	0.8	28
159	The pharmacogenetic road to avoid adverse drug reactions and therapeutic failures in revolving door patients with psychiatric illnesses: focus on the CYP2D6 isoenzymes. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 431-442.	0.4	6
160	Classifying change and heterogeneity in amyotrophic lateral sclerosis. <i>Lancet Neurology</i> , The, 2016, 15, 1111-1112.	4.9	6
161	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. <i>Nature Genetics</i> , 2016, 48, 1043-1048.	9.4	494
162	Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis. <i>Neurology</i> , 2016, 87, 237-238.	1.5	36

#	ARTICLE	IF	CITATIONS
163	High doses of incobotulinumtoxinA for the treatment of post-stroke spasticity: are they safe and effective?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 843-846.	1.5	10
164	The Role of Hearing Impairment in Cognitive Decline: Need for the Special Sense Assessment in Evaluating Cognition In Older Age. <i>Neuroepidemiology</i> , 2016, 46, 290-291.	1.1	8
165	Accuracy of clinical diagnosis of Parkinson disease. <i>Neurology</i> , 2016, 86, 566-576.	1.5	547
166	Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 259-277.	1.4	35
167	Tau aggregation inhibitors: the future of Alzheimer's disease pharmacotherapy?. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 457-461.	0.9	17
168	Stratification of ALS patients' survival: a population-based study. <i>Journal of Neurology</i> , 2016, 263, 100-111.	1.8	27
169	Non-self-sufficiency as a primary outcome measure in ALS trials. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2016, 17, 77-84.	1.1	9
170	Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin. <i>European Journal of Epidemiology</i> , 2016, 31, 229-245.	2.5	87
171	Time to generalisation as a predictor of prognosis in amyotrophic lateral sclerosis: Table 1. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 678-679.	0.9	15
172	Classification of Healthy Subjects and Alzheimer's Disease Patients with Dementia from Cortical Sources of Resting State EEG Rhythms: A Study Using Artificial Neural Networks. <i>Frontiers in Neuroscience</i> , 2016, 10, 604.	1.4	51
173	Prefrontal Activity and Connectivity with the Basal Ganglia during Performance of Complex Cognitive Tasks Is Associated with Apathy in Healthy Subjects. <i>PLoS ONE</i> , 2016, 11, e0165301.	1.1	14
174	Approach to the patient hospitalized during the Muslim Ramadan: bioethical and clinical considerations. <i>Rivista Di Psichiatria</i> , 2016, 51, 172-176.	0.6	0
175	Targeting Cognitive Frailty: Clinical and Neurobiological Roadmap for a Single Complex Phenotype. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 793-813.	1.2	108
176	Coffee Consumption Habits and the Risk of Mild Cognitive Impairment: The Italian Longitudinal Study on Aging. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 889-899.	1.2	51
177	I Need to Freeze My Gait. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 440-441.	0.8	4
178	Explanation and Elaboration of the Standards of Reporting of Neurological Disorders Checklist: A Guideline for the Reporting of Incidence and Prevalence Studies in Neuroepidemiology. <i>Neuroepidemiology</i> , 2015, 45, 113-137.	1.1	15
179	Alternative pharmacological treatment options for agitation in Alzheimer's disease. <i>Geriatric Care</i> , 2015, 1, .	0.2	1
180	Ultrasound-Guided Injection of Botulinum Toxin Type A for Piriformis Muscle Syndrome: A Case Report and Review of the Literature. <i>Toxins</i> , 2015, 7, 3045-3056.	1.5	33

#	ARTICLE	IF	CITATIONS
181	Age-related hearing impairment and frailty in Alzheimer's disease: interconnected associations and mechanisms. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 113.	1.7	67
182	Frontal assessment battery for detecting executive dysfunction in amyotrophic lateral sclerosis without dementia: a retrospective observational study. <i>BMJ Open</i> , 2015, 5, e007069.	0.8	25
183	A Multicentric Prospective Incidence Study of Guillain-Barré Syndrome in Italy. The ITANG Study. <i>Neuroepidemiology</i> , 2015, 45, 90-99.	1.1	27
184	COGNITIVE-HD study: protocol of an observational study of neurocognitive functioning and association with clinical outcomes in adults with end-stage kidney disease treated with haemodialysis. <i>BMJ Open</i> , 2015, 5, e009328.	0.8	10
185	Epidemiology of age related hearing loss: A review. <i>Hearing, Balance and Communication</i> , 2015, 13, 77-81.	0.1	20
186	Employment of higher doses of botulinum toxin type A to reduce spasticity after stroke. <i>Journal of the Neurological Sciences</i> , 2015, 350, 1-6.	0.3	42
187	Age-related hearing impairmentâ€”a risk factor and frailty marker for dementia and AD. <i>Nature Reviews Neurology</i> , 2015, 11, 166-175.	4.9	192
188	Early and severe autonomic failure: broadening the clinical phenotype of type-2 spinocerebellar ataxia. A case report. <i>Journal of Neurology</i> , 2015, 262, 224-225.	1.8	3
189	Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 879-886.	0.9	32
190	Prevalence of dementia in the oldest old: The Monzino 80â€”plus population based study. <i>Alzheimer's and Dementia</i> , 2015, 11, 258.	0.4	56
191	Sniff nasal inspiratory pressure as a prognostic factor of tracheostomy or death in amyotrophic lateral sclerosis. <i>Journal of Neurology</i> , 2015, 262, 593-603.	1.8	56
192	Amyotrophic Lateral Sclerosis: An Aging-Related Disease. <i>Current Geriatrics Reports</i> , 2015, 4, 142-153.	1.1	17
193	Cognitive Frailty: A Systematic Review of Epidemiological and Neurobiological Evidence of an Age-Related Clinical Condition. <i>Rejuvenation Research</i> , 2015, 18, 389-412.	0.9	112
194	The Use of Antidepressant Medication before and after the Diagnosis of Amyotrophic Lateral Sclerosis: A Population-Based Cohort Study. <i>Neuroepidemiology</i> , 2015, 44, 91-98.	1.1	16
195	Progresses in treating agitation: a major clinical challenge in Alzheimerâ€™s disease. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2581-2588.	0.9	43
196	Development of the standards of reporting of neurological disorders (STROND) checklist: a guideline for the reporting of incidence and prevalence studies in neuroepidemiology. <i>European Journal of Epidemiology</i> , 2015, 30, 569-576.	2.5	35
197	Development of the Standards of Reporting of Neurological Disorders (STROND) checklist. <i>Neurology</i> , 2015, 85, 821-828.	1.5	57
198	Are diabetes and amyotrophic lateral sclerosis related?. <i>Nature Reviews Neurology</i> , 2015, 11, 488-490.	4.9	22

#	ARTICLE	IF	CITATIONS
199	Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: A systematic review. <i>Journal of Nutrition, Health and Aging</i> , 2015, 19, 313-328.	1.5	154
200	Adhesive taping vs. daily manual muscle stretching and splinting after botulinum toxin type A injection for wrist and fingers spastic overactivity in stroke patients: a randomized controlled trial. <i>Clinical Rehabilitation</i> , 2015, 29, 50-58.	1.0	32
201	Systematic Reviews and Meta-Analyses in Neuroepidemiological Research: Applications and Issues. <i>Neuroepidemiology</i> , 2014, 42, 5-6.	1.1	0
202	Nutrition, frailty, and Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 221.	1.7	16
203	Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 973-986.	1.4	42
204	Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 405-419.	1.3	86
205	Å-Amyloid in CSF: A window into Parkinson disease dementia. <i>Neurology</i> , 2014, 82, 1758-1759.	1.5	2
206	Amyotrophic lateral sclerosis: new ideas from cancer. <i>Lancet Neurology</i> , The, 2014, 13, 1067-1068.	4.9	3
207	Can botulinum toxin type A injection technique influence the clinical outcome of patients with post-stroke upper limb spasticity? A randomized controlled trial comparing manual needle placement and ultrasound-guided injection techniques. <i>Journal of the Neurological Sciences</i> , 2014, 347, 39-43.	0.3	47
208	Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?. <i>Current Opinion in Psychiatry</i> , 2014, 27, 128-137.	3.1	86
209	The Prevalence of Peripheral and Central Hearing Impairment and Its Relation to Cognition in Older Adults. <i>Audiology and Neuro-Otology</i> , 2014, 19, 10-14.	0.6	102
210	Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet</i> , The, 2014, 384, 957-979.	6.3	609
211	Physical activity and amyotrophic lateral sclerosis: A European population-based case-control study. <i>Annals of Neurology</i> , 2014, 75, 708-716.	2.8	79
212	Extracorporeal Shock Wave Therapy for the Treatment of Poststroke Plantar-Flexor Muscles Spasticity: A Prospective Open-Label Study. <i>Topics in Stroke Rehabilitation</i> , 2014, 21, S17-S24.	1.0	46
213	Frontotemporal dementia and its subtypes: a genome-wide association study. <i>Lancet Neurology</i> , The, 2014, 13, 686-699.	4.9	302
214	Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1465-1476.	1.4	63
215	Prevention of Late-life Cognitive Disorders: Diet-Related Factors, Dietary Patterns, and Frailty Models. <i>Current Nutrition Reports</i> , 2014, 3, 110-129.	2.1	9
216	Long-term survival in amyotrophic lateral sclerosis: A population-based study. <i>Annals of Neurology</i> , 2014, 75, 287-297.	2.8	141

#	ARTICLE	IF	CITATIONS
217	Global, regional, and national prevalence of overweight and obesity in children and adults during 1980â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2014, 384, 766-781.	6.3	9,122
218	Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. <i>The Italian Longitudinal Study on Aging. Age</i> , 2013, 35, 441-453.	3.0	35
219	Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke. <i>Journal of Neural Transmission</i> , 2013, 120, 469-476.	1.4	32
220	Association Between Depression and Death in People With CKD: A Meta-analysis of Cohort Studies. <i>American Journal of Kidney Diseases</i> , 2013, 62, 493-505.	2.1	137
221	Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. <i>Kidney International</i> , 2013, 84, 179-191.	2.6	565
222	Risk of Guillain-BarrÃ© syndrome after 2010â€“2011 influenza vaccination. <i>European Journal of Epidemiology</i> , 2013, 28, 433-444.	2.5	41
223	Amyotrophic lateral sclerosis: a new missense mutation in the SOD1 gene. <i>Neurobiology of Aging</i> , 2013, 34, 1709.e3-1709.e5.	1.5	19
224	Predictors of survival in a series of clinically diagnosed progressive supranuclear palsy patients. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 980-985.	1.1	72
225	Frailty syndrome and the risk of vascular dementia: The Italian Longitudinal Study on Aging. <i>Alzheimer's and Dementia</i> , 2013, 9, 113-122.	0.4	140
226	Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 397-405.	1.1	68
227	Amyotrophic lateral sclerosis in Catalonia: A population based study. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 278-283.	1.1	42
228	Mitochondrial genome aberrations in skeletal muscle of patients with motor neuron disease. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 261-266.	1.1	14
229	Amyotrophic Lateral Sclerosis Descriptive Studies: Not Only Rates and Frequencies. <i>Neuroepidemiology</i> , 2013, 41, 62-63.	1.1	0
230	Cortical Thinning and Clinical Heterogeneity in Amyotrophic Lateral Sclerosis. <i>PLoS ONE</i> , 2013, 8, e80748.	1.1	76
231	Immunotherapy for Alzheimerâ€™s disease: from anti-Î²-amyloid to tau-based immunization strategies. <i>Immunotherapy</i> , 2012, 4, 213-238.	1.0	121
232	Dietary Flavonoids and Risk of Stroke in Women. <i>Stroke</i> , 2012, 43, 946-951.	1.0	167
233	Amyloid-related imaging abnormalities associated with immunotherapy in Alzheimerâ€™s disease patients. <i>Future Neurology</i> , 2012, 7, 395-401.	0.9	1
234	Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosis. <i>Neurology</i> , 2012, 79, 2315-2320.	1.5	70

#	ARTICLE	IF	CITATIONS
235	FUS mutations in sporadic amyotrophic lateral sclerosis: Clinical and genetic analysis. <i>Neurobiology of Aging</i> , 2012, 33, 837.e1-837.e5.	1.5	32
236	C9ORF72 hexanucleotide repeat expansions in the Italian sporadic ALS population. <i>Neurobiology of Aging</i> , 2012, 33, 1848.e15-1848.e20.	1.5	76
237	Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72. <i>Brain</i> , 2012, 135, 784-793.	3.7	182
238	Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset Alzheimer's disease. <i>Ageing Research Reviews</i> , 2012, 11, 87-103.	5.0	57
239	A long diagnostic delay in patients with Hereditary Haemorrhagic Telangiectasia: a questionnaire-based retrospective study. <i>Orphanet Journal of Rare Diseases</i> , 2012, 7, 33.	1.2	78
240	Current Epidemiological Approaches to the Metabolic-Cognitive Syndrome. <i>Journal of Alzheimer's Disease</i> , 2012, 30, S31-S75.	1.2	44
241	Alcohol consumption in mild cognitive impairment and dementia: harmful or neuroprotective?. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 1218-1238.	1.3	90
242	Frailty syndrome and all-cause mortality in demented patients: the Italian Longitudinal Study on Aging. <i>Age</i> , 2012, 34, 507-517.	3.0	51
243	Use of non-steroidal anti-inflammatory drugs and risk of Parkinson's disease: nested case-control study. <i>BMJ: British Medical Journal</i> , 2011, 342, d198-d198.	2.4	66
244	Therapeutic intervention for Alzheimer's disease with $\beta$ -secretase inhibitors: still a viable option?. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 325-341.	1.9	86
245	Diet and Alzheimer's disease risk factors or prevention: the current evidence. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 677-708.	1.4	231
246	Sleep disorders and the natural history of Parkinson's disease: The contribution of epidemiological studies. <i>Sleep Medicine Reviews</i> , 2011, 15, 41-50.	3.8	86
247	The epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2011, 12, 1-10.	2.3	107
248	Mediterranean Diet in Predementia and Dementia Syndromes. <i>Current Alzheimer Research</i> , 2011, 8, 520-542.	0.7	73
249	Standards for epidemiologic studies and surveillance of epilepsy. <i>Epilepsia</i> , 2011, 52, 2-26.	2.6	836
250	An exploratory study of serum urate levels in patients with amyotrophic lateral sclerosis. <i>Journal of Neurology</i> , 2011, 258, 238-243.	1.8	48
251	A Population-based study of dementia in the oldest old: the Monzino 80-plus Study. <i>BMC Neurology</i> , 2011, 11, 54.	0.8	24
252	Anti- $\beta$ -Amyloid Immunotherapy for Alzheimers Disease: Focus on Bapineuzumab. <i>Current Alzheimer Research</i> , 2011, 8, 808-817.	0.7	51

#	ARTICLE	IF	CITATIONS
253	Interacting with ß-Secretase for Treating Alzheimer's Disease: From Inhibition to Modulation. <i>Current Medicinal Chemistry</i> , 2011, 18, 5430-5447.	1.2	26
254	Coffee and Amyotrophic Lateral Sclerosis: A Possible Preventive Role. <i>American Journal of Epidemiology</i> , 2011, 174, 1002-1008.	1.6	50
255	Serum ß-acetylaspartate Level in Amyotrophic Lateral Sclerosis. <i>Archives of Neurology</i> , 2011, 68, 1308.	4.9	29
256	Vitamin E Intake and Risk of Amyotrophic Lateral Sclerosis: A Pooled Analysis of Data From 5 Prospective Cohort Studies. <i>American Journal of Epidemiology</i> , 2011, 173, 595-602.	1.6	103
257	Can Mortality Data Be Used to Estimate Amyotrophic Lateral Sclerosis Incidence?. <i>Neuroepidemiology</i> , 2011, 36, 29-38.	1.1	61
258	Depression and Incident Stroke in Women. <i>Stroke</i> , 2011, 42, 2770-2775.	1.0	91
259	Smoking and Risk of Amyotrophic Lateral Sclerosis. <i>Archives of Neurology</i> , 2011, 68, 207-13.	4.9	117
260	Incidence of amyotrophic lateral sclerosis in Europe. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 385-390.	0.9	648
261	Prognostication after cardiac arrest and hypothermia: A prospective study. <i>Annals of Neurology</i> , 2010, 67, 301-307.	2.8	488
262	Refractory status epilepticus: A prospective observational study. <i>Epilepsia</i> , 2010, 51, 251-256.	2.6	331
263	Smoking and the risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 1249-1252.	0.9	92
264	Natural history of upper motor neuron-dominant ALS. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2010, 11, 424-429.	2.3	29
265	Ischemic stroke. <i>Neurology</i> , 2010, 75, 1576-1577.	1.5	2
266	Can dementia be prevented?. <i>BMJ: British Medical Journal</i> , 2010, 341, c4201-c4201.	2.4	1
267	Association of smoking with amyotrophic lateral sclerosis risk and survival in men and women: a prospective study. <i>BMC Neurology</i> , 2010, 10, 6.	0.8	47
268	REVIEW: ß-Secretase Inhibitors for the Treatment of Alzheimer's Disease: The Current State. <i>CNS Neuroscience and Therapeutics</i> , 2010, 16, 272-284.	1.9	63
269	Amyotrophic lateral sclerosis, physical exercise, trauma and sports: Results of a population-based pilot case-control study. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2010, 11, 289-292.	2.3	110
270	Homocysteine levels and amyotrophic lateral sclerosis: A possible link. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2010, 11, 140-147.	2.3	48



#	ARTICLE	IF	CITATIONS
271	Incidence and remaining lifetime risk of Parkinson disease in advanced age. <i>Neurology</i> , 2009, 72, 432-438.	1.5	222
272	Prevalence of Primary Focal or Segmental Dystonia in Adults in the District of Foggia, Southern Italy: A Service-Based Study. <i>Neuroepidemiology</i> , 2009, 33, 117-123.	1.1	16
273	Migraine frequency and risk of cardiovascular disease in women. <i>Neurology</i> , 2009, 73, 581-588.	1.5	140
274	Coffee Consumption and Risk of Stroke in Women. <i>Circulation</i> , 2009, 119, 1116-1123.	1.6	135
275	Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia. <i>Movement Disorders</i> , 2009, 24, 1028-1033.	2.2	53
276	Prognostic factors in ALS: A critical review. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2009, 10, 310-323.	2.3	839
277	Status Epilepticus Severity Score (STESS). <i>Journal of Neurology</i> , 2008, 255, 1561-1566.	1.8	326
278	Perceived imbalance and risk of Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 613-616.	2.2	48
279	Amyotrophic lateral sclerosis and soccer: A different epidemiological approach strengthen the previous findings. <i>Journal of the Neurological Sciences</i> , 2008, 269, 187-188.	0.3	12
280	Predictors of long survival in amyotrophic lateral sclerosis: A population-based study. <i>Journal of the Neurological Sciences</i> , 2008, 268, 28-32.	0.3	65
281	Outcome measures and prognostic indicators in patients with amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2008, 9, 163-167.	2.3	39
282	Prospective Cohort Study of Type 2 Diabetes and the Risk of Parkinson's Disease. <i>Diabetes Care</i> , 2008, 31, 2003-2005.	4.3	147
283	Status Epilepticus Without an Underlying Cause and Risk of Death. <i>Archives of Neurology</i> , 2008, 65, 221-4.	4.9	32
284	Cigarette Smoking and Dementia. <i>Epidemiology</i> , 2008, 19, 448-450.	1.2	140
285	Low Incidence of Stroke in Southern Italy. <i>Stroke</i> , 2008, 39, 2923-2928.	1.0	21
286	Primary Prevention of Stroke by Healthy Lifestyle. <i>Circulation</i> , 2008, 118, 947-954.	1.6	393
287	Dietary Iron Intake and Risk of Parkinson's Disease. <i>American Journal of Epidemiology</i> , 2008, 168, 1381-1388.	1.6	83
288	Adherence to a DASH-Style Diet and Risk of Coronary Heart Disease and Stroke in Women. <i>Archives of Internal Medicine</i> , 2008, 168, 713.	4.3	1,118

#	ARTICLE	IF	CITATIONS
289	IN-HOSPITAL MORTALITY OF GENERALIZED CONVULSIVE STATUS EPILEPTICUS: A LARGE US SAMPLE. <i>Neurology</i> , 2008, 70, 1939-1940.	1.5	3
290	Incidence of cardiovascular disease and cancer in advanced age: prospective cohort study. <i>BMJ: British Medical Journal</i> , 2008, 337, a2467-a2467.	2.4	136
291	Migraine, vascular risk, and cardiovascular events in women: prospective cohort study. <i>BMJ: British Medical Journal</i> , 2008, 337, a636-a636.	2.4	211
292	The Metabolic Syndrome. <i>Stroke</i> , 2008, 39, 1068-1069.	1.0	7
293	Myoclonic Encephalopathy after Exposure to Trichloroethylene. <i>Industrial Health</i> , 2008, 46, 635-637.	0.4	4
294	Gout and risk of Parkinson disease. <i>Neurology</i> , 2007, 69, 1696-1700.	1.5	158
295	The Heterogeneity of Amyotrophic Lateral Sclerosis: A Possible Explanation of Treatment Failure. <i>Current Medicinal Chemistry</i> , 2007, 14, 3185-3200.	1.2	62
296	Efficacy of riluzole: Who are the patients enrolled in the studies?. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2007, 8, 124-125.	2.3	3
297	Migraine and Risk of Cardiovascular Disease in Men. <i>Archives of Internal Medicine</i> , 2007, 167, 795.	4.3	202
298	Erectile Function and Risk of Parkinson's Disease. <i>American Journal of Epidemiology</i> , 2007, 166, 1446-1450.	1.6	102
299	Prospective Study of Type 1 and Type 2 Diabetes and Risk of Stroke Subtypes: The Nurses' Health Study. <i>Diabetes Care</i> , 2007, 30, 1730-1735.	4.3	175
300	Amyotrophic lateral sclerosis: A global threat with a possible difference in risk across ethnicities. <i>Neurology</i> , 2007, 68, E17-E17.	1.5	2
301	A Prospective Cohort Study of Cancer Incidence Following the Diagnosis of Parkinson's Disease. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 1260-1265.	1.1	140
302	Body Mass Index and Risk of Parkinson's Disease: A Prospective Cohort Study. <i>American Journal of Epidemiology</i> , 2007, 166, 1186-1190.	1.6	52
303	Prospective study of dietary pattern and risk of Parkinson disease. <i>American Journal of Clinical Nutrition</i> , 2007, 86, 1486-1494.	2.2	281
304	Prospective case-control study of nonfatal cancer preceding the diagnosis of parkinson's disease. <i>Cancer Causes and Control</i> , 2007, 18, 705-711.	0.8	49
305	ALS multidisciplinary clinic and survival. <i>Journal of Neurology</i> , 2007, 254, 1107-1112.	1.8	65
306	Predictors of delay in the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: A population-based study. <i>Journal of the Neurological Sciences</i> , 2006, 250, 45-49.	0.3	85

#	ARTICLE	IF	CITATIONS
307	The epidemiology of ALS and the role of population-based registries. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2006, 1762, 1150-1157.	1.8	168
308	Association of depression with Alzheimer's disease and vascular dementia in an elderly Arab population of Wadi-Ara, Israel. <i>International Journal of Geriatric Psychiatry</i> , 2006, 21, 246-251.	1.3	21
309	Blood donations, iron stores, and risk of Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 835-838.	2.2	34
310	Migraine and Risk of Cardiovascular Disease in Women. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 283.	3.8	478
311	Can We Escape Stroke and Alzheimer Disease?. <i>Stroke</i> , 2006, 37, 279-280.	1.0	9
312	A clinical score for prognosis of status epilepticus in adults. <i>Neurology</i> , 2006, 66, 1736-1738.	1.5	185
313	Unreported Financial Disclosures in a Study of Migraine and Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 648.	3.8	4
314	Association Between Migraine and Cardiovascular Disease in Women—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 2677.	3.8	0
315	Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. <i>Neurology</i> , 2006, 66, 1097-1099.	1.5	133
316	Dietary Carbohydrates and Glycated Proteins in the Blood in Non Diabetic Subjects. <i>Journal of the American College of Nutrition</i> , 2005, 24, 22-29.	1.1	20
317	Methodologic Issues in Studies of Mortality Following Epilepsy: Measures, Types of Studies, Sources of Cases, Cohort Effects, and Competing Risks. <i>Epilepsia</i> , 2005, 46, 3-7.	2.6	39
318	Mortality after a First Episode of Status Epilepticus in the United States and Europe. <i>Epilepsia</i> , 2005, 46, 46-48.	2.6	157
319	The Role of Early Life Environmental Risk Factors in Parkinson Disease: What Is the Evidence?. <i>Environmental Health Perspectives</i> , 2005, 113, 1234-1238.	2.8	117
320	Cigarette smoking and the progression of multiple sclerosis. <i>Brain</i> , 2005, 128, 1461-1465.	3.7	242
321	Refractory Status Epilepticus. <i>Archives of Neurology</i> , 2005, 62, 1698.	4.9	369
322	Brain Abscess: A Need to Screen for Pulmonary Arteriovenous Malformations. <i>Neuroepidemiology</i> , 2005, 24, 76-78.	1.1	19
323	Apolipoprotein E, cardiovascular disease and cognitive function in aging women. <i>Neurobiology of Aging</i> , 2005, 26, 475-484.	1.5	59
324	Migraine is associated with chest symptoms but not cardiac events. <i>Neurology</i> , 2004, 63, 2209-2210.	1.5	5

#	ARTICLE	IF	CITATIONS
325	Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years. <i>BMJ: British Medical Journal</i> , 2004, 328, 548.	2.4	162
326	Folate Intake and Risk of Parkinson's Disease. <i>American Journal of Epidemiology</i> , 2004, 160, 368-375.	1.6	60
327	A prospective study of alcoholism and the risk of Parkinson's disease. <i>Journal of Neurology</i> , 2004, 251, vii14-vii17.	1.8	41
328	Fructosamine, glycated hemoglobin, and dietary carbohydrates. <i>Clinica Chimica Acta</i> , 2004, 340, 139-147.	0.5	21
329	Apolipoprotein E genotype does not influence the progression of multiple sclerosis. <i>Journal of Neurology</i> , 2003, 250, 1094-1098.	1.8	40
330	Reliability of the El Escorial Diagnostic Criteria for Amyotrophic Lateral Sclerosis. <i>Neuroepidemiology</i> , 2002, 21, 265-270.	1.1	58
331	The ever-stimulating association of smoking and coffee and Parkinson's disease. <i>Annals of Neurology</i> , 2002, 52, 261-262.	2.8	22
332	Treatment of Nonfebrile Status Epilepticus in Rochester, Minn, From 1965 Through 1984. <i>Mayo Clinic Proceedings</i> , 2001, 76, 39-41.	1.4	29
333	Time Trends in Incidence, Mortality, and Case-Fatality after First Episode of Status Epilepticus. <i>Epilepsia</i> , 2001, 42, 1031-1035.	2.6	101
334	Morbidity of Nonfebrile Status Epilepticus in Rochester, Minnesota, 1965-1984. <i>Epilepsia</i> , 1998, 39, 829-832.	2.6	42
335	Risk of unprovoked seizure after acute symptomatic seizure: Effect of status epilepticus. <i>Annals of Neurology</i> , 1998, 44, 908-912.	2.8	241
336	Diet and Parkinson's disease. <i>Neurology</i> , 1997, 49, 310-310.	1.5	12
337	Short-Term Mortality After a First Episode of Status Epilepticus. <i>Epilepsia</i> , 1997, 38, 1344-1349.	2.6	286
338	Dietary lipids and antioxidants in Parkinson's disease: A population-based, case-control study. <i>Annals of Neurology</i> , 1996, 39, 89-94.	2.8	263
339	Blood-cerebrospinal fluid barrier permeability to serum IgG subfractions and measurement of intrathecal IgG synthesis. <i>Journal of the Neurological Sciences</i> , 1986, 73, 325-338.	0.3	1
340	Heterogeneous models for blood-cerebrospinal fluid barrier permeability to serum proteins in normal and abnormal cerebrospinal fluid/serum protein concentration gradients. <i>Journal of the Neurological Sciences</i> , 1984, 64, 245-258.	0.3	24
341	Prognostic factors in ALS: A critical review. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 0, , 1-14.	2.3	16
342	Radiomics Model for Frontotemporal Dementia Diagnosis Using T1-Weighted MRI. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	5

#	ARTICLE	IF	CITATIONS
343	The Role of Graph Theory in Evaluating Brain Network Alterations in Frontotemporal Dementia. Frontiers in Neurology, 0, 13, .	1.1	7